{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:04:10Z","timestamp":1792177450148,"version":"4.4.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ncl.2018.01.002","type":"journal-article","created":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T18:14:40Z","timestamp":1523470480000},"page":"253-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":193,"title":["Generalized Myasthenia Gravis"],"prefix":"10.1016","volume":"36","author":[{"given":"Michael K.","family":"Hehir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ncl.2018.01.002_bib1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1196\/annals.1254.053","article-title":"The epidemiology of myasthenia gravis","volume":"998","author":"Phillips","year":"2003","journal-title":"Ann New York Acad Sci"},{"key":"10.1016\/j.ncl.2018.01.002_bib2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000279334","article-title":"The incidence of myasthenia gravis: a systematic literature review","volume":"34","author":"McGrogan","year":"2010","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.ncl.2018.01.002_bib3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A\u00a0systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"key":"10.1016\/j.ncl.2018.01.002_bib4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1212\/WNL.0b013e3181ad53c2","article-title":"Seropositive myasthenia gravis: a nationwide epidemiologic study","volume":"73","author":"Heldal","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.01.002_bib5","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/j.1468-1331.2010.03089.x","article-title":"Myasthenia gravis requiring pyridostigmine treatment in a national population cohort","volume":"17","author":"Andersen","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ncl.2018.01.002_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.002_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1600-0404.1992.tb05050.x","article-title":"Myasthenia gravis in Hong Kong Chinese. 1.\u00a0epidemiology and adult disease","volume":"86","author":"Yu","year":"1992","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.ncl.2018.01.002_bib8","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1212\/WNL.42.10.1888","article-title":"The epidemiology of myasthenia gravis in central and western Virginia","volume":"42","author":"Phillips","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.01.002_bib9","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/mus.21191","article-title":"Racial differences in myasthenia gravis in Alabama","volume":"39","author":"Oh","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.002_bib10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/01.wnl.0000254620.45529.97","article-title":"Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis","volume":"68","author":"Deymeer","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.01.002_bib11","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1749-6632.1987.tb51317.x","article-title":"The course of myasthenia gravis and therapies affecting outcome","volume":"505","author":"Grob","year":"1987","journal-title":"Ann New York Acad Sci"},{"key":"10.1016\/j.ncl.2018.01.002_bib12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1172-2-44","article-title":"Myasthenia gravis","volume":"2","author":"Juel","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ncl.2018.01.002_bib13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/mus.21533","article-title":"Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience","volume":"41","author":"Pasnoor","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.002_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.002_bib15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1055\/s-0035-1558975","article-title":"Myasthenia gravis","volume":"35","author":"Gwathmey","year":"2015","journal-title":"Semin Neurol"},{"key":"10.1016\/j.ncl.2018.01.002_bib16","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ncl.2018.01.002_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jns.2007.04.045","article-title":"Myasthenic crisis: guidelines for prevention and treatment","volume":"261","author":"Jani-Acsadi","year":"2007","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.ncl.2018.01.002_bib18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/mus.24929","article-title":"Correlation of single-breath count test and neck flexor muscle strength with spirometry in myasthenia gravis","volume":"53","author":"Elsheikh","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.002_bib19","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/mus.20403","article-title":"Pulmonary function tests and blood gases in worsening myasthenia gravis","volume":"32","author":"Thieben","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.002_bib20","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1212\/01.wnl.0000327669.75695.38","article-title":"Treatment of ocular symptoms in myasthenia gravis","volume":"71","author":"Bhanushali","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.01.002_bib21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.24769","article-title":"Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial","volume":"53","author":"Benatar","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.002_bib22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s004280050044","article-title":"Pathogenesis of myasthenia gravis","volume":"430","author":"Marx","year":"1997","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ncl.2018.01.002_bib23","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1212\/01.WNL.0000150587.71497.B6","article-title":"Thymus changes in anti-MuSK-positive and -negative myasthenia gravis","volume":"64","author":"Lauriola","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.01.002_bib24","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ncl.2018.01.002_bib25","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mus.23944","article-title":"Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?","volume":"49","author":"Sanders","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.002_bib26","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG","volume":"57","author":"Leite","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2018.01.002_bib27","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.autrev.2013.03.004","article-title":"Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase","volume":"12","author":"Evoli","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ncl.2018.01.002_bib28","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/ana.410130506","article-title":"Myasthenia gravis in children: long-term follow-up","volume":"13","author":"Rodriguez","year":"1983","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2018.01.002_bib29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.002_bib30","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/WNL.0000000000000478","article-title":"Anti-agrin autoantibodies in myasthenia gravis","volume":"82","author":"Gasperi","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.01.002_bib31","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ncl.2018.01.002_bib32","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.autrev.2014.08.039","article-title":"Cortactin autoantibodies in myasthenia gravis","volume":"13","author":"Gallardo","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ncl.2018.01.002_bib33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A\u00a0comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.ncl.2018.01.002_bib34","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/01.phm.0000171169.79816.4c","article-title":"Advances in the diagnosis of neuromuscular junction disorders","volume":"84","author":"Meriggioli","year":"2005","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.ncl.2018.01.002_bib35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.expneurol.2015.01.011","article-title":"Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases","volume":"270","author":"Rodriguez Cruz","year":"2015","journal-title":"Exp Neurol"},{"key":"10.1016\/j.ncl.2018.01.002_bib36","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis","volume":"72","author":"Rodriguez Cruz","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ncl.2018.01.002_bib37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/mus.10294","article-title":"Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in\u00a0vitro","volume":"27","author":"Skeie","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.002_bib38","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1468-1331.2007.01785.x","article-title":"Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features","volume":"14","author":"Romi","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ncl.2018.01.002_bib39","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1212\/WNL.10.11.1007","article-title":"Diagnosis and treatment of myasthenia gravis in infancy, childhood, and adolescence: a study of 51 patients","volume":"10","author":"Millichap","year":"1960","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.01.002_bib40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1055\/s-2004-829591","article-title":"Autoimmune myasthenia gravis in childhood","volume":"24","author":"Andrews","year":"2004","journal-title":"Semin Neurol"},{"key":"10.1016\/j.ncl.2018.01.002_bib41","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0960-8966(98)00077-7","article-title":"Juvenile myasthenia gravis with prepubertal onset","volume":"8","author":"Evoli","year":"1998","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ncl.2018.01.002_bib42","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1177\/088307380201700516","article-title":"Gender prevalence in childhood multiple sclerosis and myasthenia gravis","volume":"17","author":"Haliloglu","year":"2002","journal-title":"J\u00a0Child Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2018.01.002_bib43","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/CND.0b013e31821c5634","article-title":"Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response","volume":"13","author":"Mittal","year":"2011","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"key":"10.1016\/j.ncl.2018.01.002_bib44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/CND.0b013e318253a48e","article-title":"Juvenile myasthenia gravis: a twenty-year experience","volume":"14","author":"Castro","year":"2013","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"key":"10.1016\/j.ncl.2018.01.002_bib45","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ajo.2010.05.002","article-title":"Visual and systemic outcomes in pediatric ocular myasthenia gravis","volume":"150","author":"Pineles","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ncl.2018.01.002_bib46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1600-0404.2006.00646.x","article-title":"Myasthenia gravis in children: a longitudinal study","volume":"114","author":"Ashraf","year":"2006","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.ncl.2018.01.002_bib47","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1468-1331.2006.01538.x","article-title":"Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care","volume":"14","author":"Hoff","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ncl.2018.01.002_bib48","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/CND.0000000000000034","article-title":"Treatment-refractory myasthenia gravis","volume":"15","author":"Silvestri","year":"2014","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"key":"10.1016\/j.ncl.2018.01.002_bib49","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.01.002_bib50","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/mus.21521","article-title":"Rituximab in the management of refractory myasthenia gravis","volume":"41","author":"Zebardast","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.002_bib51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamaneurol.2016.4367","article-title":"Rituximab in treatment-refractory myasthenia gravis","volume":"74","author":"Silvestri","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ncl.2018.01.002_bib52","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia gravis clinical study group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2018.01.002_bib53","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.01.002_bib54","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/postgradmedj-2013-132105","article-title":"Acute neuromuscular respiratory failure: a population-based study of aetiology and outcome in Northern Ireland","volume":"90","author":"Carr","year":"2014","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.ncl.2018.01.002_bib55","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.01.002_bib56","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jama.1953.02940230001001","article-title":"Course and management of myasthenia gravis","volume":"153","author":"Grob","year":"1953","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.ncl.2018.01.002_bib57","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/0021-9681(58)90009-2","article-title":"Myasthenia gravis: current status of pathogenesis, clinical manifestations, and management","volume":"8","author":"Grob","year":"1958","journal-title":"J\u00a0Chronic Dis"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861918300021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861918300021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T10:29:54Z","timestamp":1534933794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861918300021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0733861918300021"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2018.01.002","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734270246.793552106","asserted-by":"object"}]},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Generalized Myasthenia Gravis","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2018.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}